Theratechnologies Completes Acquisition by Future Pak for $3.01 Per Share Plus Contingent Value Rights
ByAinvest
Thursday, Sep 25, 2025 1:22 pm ET1min read
THTX--
Theratechnologies, a commercial-stage biopharmaceutical company, has completed its acquisition by Future Pak. The company's shares have been acquired for $3.01 per share in cash, plus one contingent value right (CVR) per share for additional payments of up to $1.19 per CVR if certain milestones are achieved. The CVRs are recorded in a register kept by the CVR agent and are not evidenced by a certificate or any other instrument. The shares will be delisted from the Toronto Stock Exchange and Nasdaq Capital Market.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet